Organization
Asklepios Biopharmaceutical
5 clinical trials
2 abstracts
Clinical trial
A Phase 2, Randomized, Double-blind, Sham Surgery-controlled Study of the Efficacy and Safety of Intraputaminal AAV2-GDNF in the Treatment of Adults With Moderate Stage Parkinson's DiseaseStatus: Not yet recruiting, Estimated PCD: 2027-11-30
Clinical trial
Phase 1 Open Label, Dose Escalation Trial of Intracoronary Infusion of NAN-101 in Subjects With NYHA Class III Heart FailureStatus: Recruiting, Estimated PCD: 2026-12-31
Clinical trial
A Two-part Multicenter Study: a Randomized, Double-blind, Placebo-controlled Dose-escalation Safety Phase (Part 1) Followed by Double-blind, Placebo-controlled, Adaptive Phase (Part 2) Study to Evaluate the Safety and Efficacy of AB-1003 in Adult Subjects With LGMD2I/R9 Mutations in the Gene Encoding Fukutin Related Protein (FKRP)Status: Recruiting, Estimated PCD: 2028-12-01
Clinical trial
A Phase 1 Study of the Safety of AAV2/8-LSPhGAA (ACTUS-101) in Late-onset Pompe DiseaseStatus: Active (not recruiting), Estimated PCD: 2022-09-30
Clinical trial
A Phase 2, Adaptive, Double-blinded, Placebo Controlled, Randomized, Multi-center Trial to Evaluate the Efficacy, Safety and Tolerability of Intracoronary Infusion of AB-1002 in Adult Subjects With New York Heart Association (NYHA) Class III Heart Failure and Non-ischemic CardiomyopathyStatus: Recruiting, Estimated PCD: 2030-12-01
Abstract
Anakinra first- or second-line in systemic juvenile idiopathic arthritis patientsOrg: Asklepios Biopharmaceutical, Sankt Augustin University Cologne, Cologne Olga Hospital, Stuttgart Hamburg Centre Paediatric Rheumatology, Hamburg, Germany,
Abstract
ANALYSIS OF UVEITIS EVENTS IN THE BIOLOGICS IN PEDIATRIC RHEUMATOLOGY (BIKER)-REGISTRY Org: Asklepios Biopharmaceutical, Hamburger Zentrum für Kinder- und Jugendrheumatologie, Hamburg, Germany, Charité University Medicine Berlin, RWTH Aachen University, Prof Hess Childrens Hospital,